表紙:サイトメガロウイルス治療の世界市場2023-2030
市場調査レポート
商品コード
1311871

サイトメガロウイルス治療の世界市場2023-2030

Global Cytomegalovirus Treatment Market 2023-2030

出版日: | 発行: Orion Market Research | ページ情報: 英文 200 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
サイトメガロウイルス治療の世界市場2023-2030
出版日: 2023年06月27日
発行: Orion Market Research
ページ情報: 英文 200 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

サイトメガロウイルス(CMV)治療の世界市場は、予測期間(2023~2030年)にCAGR 5.8%で成長すると予測されています。CMV網膜炎や先天性CMV感染症の有病率の上昇に加え、これらの疾患の治療や診断に関する認識を高める取り組みが増加していることが、CMV治療市場の成長を促進する主な要因となっています。例えば、CDCの最新データによると、2022年5月現在、米国では毎年約150人の乳幼児がCMV感染症を持って生まれており、そのうちの数人は長期的な健康問題を抱えています。乳幼児がCMVに感染すると、成人の同様の感染に関連するインターフェロン反応が減弱します。

同じ情報源によれば、CMV感染とCMV感染の再活性化のリスクは妊娠中にも報告されており、先天性CMV感染につながる可能性もあります。このように、疾病負担の増加は、効果的な治療オプションに対する需要を生み出し、CMV治療市場の成長を促進すると予想されています。新薬開発のための臨床試験研究の新興国市場が、世界市場の成長を牽引すると思われます。

2022年4月、研究者らは、妊娠中にCMV感染が胎児に移行するリスクを推定する計算機外部リンクを開発しました。この先天性CMV感染は、母体のCMV一次感染例の約20.0%~40.0%で発生します。個人の特徴に基づいて先天性CMVの可能性を予測する非侵襲的な方法を提供することで、この計算機はヘルスケア提供者がCMVに感染している妊婦にカウンセリングを行うのをサポートする可能性があります。このような開発により、乳児の感染率が低下することが期待されます。

セグメント別展望

地域別展望

世界のサイトメガロウイルス治療市場はアジア太平洋地域が大きなCAGRで成長する見込み

すべての地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予想されています。この地域の成長は、CMV治療薬の主要な応用分野の一つである幹細胞研究に対する連邦政府の資金援助が拡大していることに起因しています。インドでは、バイオテクノロジー省(DBT)が幹細胞の基礎生物学、早期・後期トランスレーショナル研究、治療応用の可能性を秘めた遺伝子編集技術の開発、様々なヒト疾患の動物モデル作製などのプロジェクトを支援しています。2021年現在、この分野でDBTが過去3年間と今年度に放出した資金は8,960万米ドルです。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • F. Hoffmann-La Roche Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Gilead Sciences, Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Teva Canada Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • サイトメガロウイルス治療の世界市場:薬剤タイプ別
    • シドホビル
    • フォスカルネット
    • バルガンシクロビル
    • ガンシクロビル
  • サイトメガロウイルス治療の世界市場:用途別
    • 幹細胞移植
    • 臓器移植
    • 先天性CMV感染症
    • その他の用途
  • サイトメガロウイルス治療の世界市場:流通チャネル別
    • 病院薬局
    • 小売薬局
    • eコマース

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • AiCuris Anti-infective Cures GmbH
  • Chimerix, Inc.
  • Clinigen Group PLC
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi Canada
  • Genentech Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Mylan N.V
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Inc
  • Thermo Fisher Scientific, Inc.
  • Vical, Inc.
  • ViroPharma, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027352

Title: Global Cytomegalovirus Treatment Market Size, Share & Trends Analysis Report by Drug Type (Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other Application), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and E-commerce), Forecast Period (2023-2030).

The global cytomegalovirus (CMV) treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The rising prevalence of CMV retinitis and congenital CMV infection, along with increasing initiatives to create awareness regarding treatments and diagnosis of these conditions is a key factor driving the growth of the CMV treatment market. For instance, as per the updated CDC data, as of May 2022, in the US, around 150 infants are born with CMV infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult.

As per the same source, CMV infection and the risk of reactivation of CMV infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is anticipated to create the demand for effective treatment options, thereby driving the CMV treatment market growth. The increasing clinical trial studies for the development of new drugs are likely to drive the growth of the global market.

In April 2022, the researchers have developed a calculator external link to estimate the risk that CMV infection will pass to a fetus during pregnancy. This congenital CMV infection occurs in about 20.0% to 40.0% of cases of primary maternal CMV infection. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, the calculator may support healthcare provider to counsel pregnant people with CMV. Such developments are anticipated to lower the infection rate in infants.

Segmental Outlook

The global cytomegalovirus treatment market is segmented on the drug type, application, and distribution channel. Based on the drug type, the market is sub-segmented into Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir. Based on the application, the market is sub-segmented into stem cell transplantation, organ transplantation, congenital CMV infection, and other application. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and E-commerce.

Regional Outlook

The global cytomegalovirus treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of key market players along with high healthcare expenditure. The increasing incidences of cytomegalovirus infections along with increasing awareness among consumers also play a crucial role in the regional market growth. For instance, the article published by the National Institute of Neurological Disorders and Stroke (NINDS) in July 2022 mentioned that CMV infected about 50.0% to 80.0% of adults by the age of 40 and is one of the most congenital infections in the US annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. Such an increased incidence of CMV among the North American population to create higher demand for effective treatment thereby is driving the growth of the market.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Cytomegalovirus Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing federal funding for stem cell research, which is one of the core application areas of CMV drugs. In India, the Department of Biotechnology (DBT) has supported projects for basic biology of stem cells; early and late translational research; developing gene editing technology for potential therapeutic applications and creation of animal models for various human diseases. As of 2021, the funds released by the DBT during the last three years and the current year in this area is $89.6 million.

Market Players Outlook

The major companies serving the cytomegalovirus treatment market include: F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies including funding for R&D, and new drug development, to stay competitive in the market. For instance, in September 2022, Takeda announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cytomegalovirus treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Gilead Sciences, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Canada Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cytomegalovirus Treatment Market by Drug Type
    • 4.1.1. Cidofovir
    • 4.1.2. Foscarnet
    • 4.1.3. Valganciclovir
    • 4.1.4. Ganciclovir
  • 4.2. Global Cytomegalovirus Treatment Markey by Application
    • 4.2.1. Stem Cell Transplantation
    • 4.2.2. Organ Transplantation
    • 4.2.3. Congenital CMV Infection
    • 4.2.4. Other Application
  • 4.3. Global Cytomegalovirus Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. E-Commerce

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AiCuris Anti-infective Cures GmbH
  • 6.2. Chimerix, Inc.
  • 6.3. Clinigen Group PLC
  • 6.4. F. Hoffmann-La Roche AG
  • 6.5. Fresenius Kabi Canada
  • 6.6. Genentech Inc.
  • 6.7. Gilead Sciences, Inc.
  • 6.8. GlaxoSmithKline plc
  • 6.9. Merck & Co., Inc.
  • 6.10. Moderna, Inc.
  • 6.11. Mylan N.V
  • 6.12. Pfizer Inc.
  • 6.13. Takeda Pharmaceuticals
  • 6.14. Teva Pharmaceuticals Inc
  • 6.15. Thermo Fisher Scientific, Inc.
  • 6.16. Vical, Inc.
  • 6.17. ViroPharma, Inc.